PE20060768A1 - Composicion farmaceutica que comprende hidroclorotiazida y telmisartano - Google Patents
Composicion farmaceutica que comprende hidroclorotiazida y telmisartanoInfo
- Publication number
- PE20060768A1 PE20060768A1 PE2005001465A PE2005001465A PE20060768A1 PE 20060768 A1 PE20060768 A1 PE 20060768A1 PE 2005001465 A PE2005001465 A PE 2005001465A PE 2005001465 A PE2005001465 A PE 2005001465A PE 20060768 A1 PE20060768 A1 PE 20060768A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical composition
- hydrochlorothiazide
- composition including
- telmisartane
- composition
- Prior art date
Links
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002003 hydrochlorothiazide Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 abstract 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- 239000005537 C09CA07 - Telmisartan Substances 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960005187 telmisartan Drugs 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 229920002261 Corn starch Polymers 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000008120 corn starch Substances 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 235000010356 sorbitol Nutrition 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicinal Preparation (AREA)
Abstract
REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE 80 MG DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA II TAL COMO EL TELMISARTANO Y 25 MG DE UN DIURETICO TAL COMO HIDROCLOROTIAZIDA. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA QUE PUEDE DIVIDIRSE EN MITADES QUE COMPRENDE 160 MG DE TELMISARTANO Y 50 MG DE HIDROCLOROTIAZIDA. LA COMPOSICION PUEDE CONTENER, ADEMAS, HIDROXIDO DE SODIO, MEGLUMINA, POVIDONA, SORBITOL, ESTEARATO DE MAGNESIO, LACTOSA MONOHIDRATADA, CELULOSA MICROCRISTALINA, ALMIDON DE MAIZ, ENTRE OTROS. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE LA HIPERTENSION, ACCIDENTES CEREBRO VASCULARES, INSUFICIENCIA CARDIACA CONGESTIVA, RESISTENCIA A LA INSULINA, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63706204P | 2004-12-17 | 2004-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060768A1 true PE20060768A1 (es) | 2006-09-29 |
Family
ID=35589356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001465A PE20060768A1 (es) | 2004-12-17 | 2005-12-15 | Composicion farmaceutica que comprende hidroclorotiazida y telmisartano |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1827424A1 (es) |
| JP (1) | JP2008524136A (es) |
| KR (1) | KR20070097511A (es) |
| CN (1) | CN101080225A (es) |
| AR (1) | AR052052A1 (es) |
| AU (1) | AU2005315855A1 (es) |
| BR (1) | BRPI0519656A2 (es) |
| CA (1) | CA2589493A1 (es) |
| EA (1) | EA200701159A1 (es) |
| IL (1) | IL183944A0 (es) |
| NO (1) | NO20072325L (es) |
| PE (1) | PE20060768A1 (es) |
| TW (1) | TW200637546A (es) |
| UY (1) | UY29274A1 (es) |
| WO (1) | WO2006063737A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| US8637078B2 (en) | 2005-11-24 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Bilayer tablet comprising telmisartan and diuretic |
| EP1970053A1 (en) * | 2007-03-14 | 2008-09-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical composition |
| BRPI0817822A2 (pt) † | 2007-10-19 | 2015-03-31 | Otsuka Pharma Co Ltd | Preparação sólida farmacêutica do tipo matriz |
| EP2203158A4 (en) | 2007-10-30 | 2012-12-26 | Reddys Lab Ltd Dr | PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE |
| SI2252273T1 (sl) | 2008-03-19 | 2017-06-30 | Ratiopharm Gmbh | Trdni farmacevtski sestavek, ki obsega nepeptidni antagonist receptorja angiotenzina II in diuretik |
| CA2732018C (en) * | 2008-07-31 | 2017-07-04 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical composition |
| GB0822170D0 (en) * | 2008-12-04 | 2009-01-14 | Arrow Int Ltd | Telmisartan with diuretic formulations |
| ES2415357T3 (es) | 2009-06-19 | 2013-07-25 | Krka Tovarna Zdravil, D.D., Novo Mesto | Procedimiento para la preparación de telmisartán |
| EP2448576A2 (en) * | 2009-07-02 | 2012-05-09 | Mahmut Bilgic | Solubility enhancing pharmaceutical composition |
| WO2011002425A2 (en) * | 2009-07-02 | 2011-01-06 | Bilgig Mahmut | Pharmaceutical composition increasing solubility and stability |
| TR200906506A2 (tr) | 2009-08-24 | 2011-03-21 | Bi̇lgi̇ç Mahmut | Telmisartan içeren katı dozaj formları. |
| WO2011161123A2 (en) | 2010-06-21 | 2011-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Multilayer pharmaceutical tablet comprising telmisartan and a diuretic |
| JP6379044B2 (ja) * | 2013-01-31 | 2018-08-22 | 沢井製薬株式会社 | テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤 |
| EP3025711B1 (en) * | 2013-07-23 | 2020-11-18 | Daiichi Sankyo Company, Limited | Medicine for preventing or treating hypertension |
| CN106562973A (zh) * | 2016-11-06 | 2017-04-19 | 成都先先先生物科技有限公司 | 一种抗高血压药物复方制剂 |
| CN107501192A (zh) * | 2017-08-15 | 2017-12-22 | 中国科学院上海药物研究所 | 替米沙坦与氢氯噻嗪的共晶 |
| CN108653227A (zh) * | 2018-08-09 | 2018-10-16 | 湖北舒邦药业有限公司 | 一种替米沙坦氢氯噻嗪片及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4229085C2 (de) * | 1992-09-01 | 1996-07-11 | Boehringer Mannheim Gmbh | Längliche, teilbare Tablette |
| CN101352421A (zh) * | 2002-01-16 | 2009-01-28 | 贝林格尔英格海姆法玛两合公司 | 一种制备基本上非结晶形式的替米沙坦的方法 |
-
2005
- 2005-12-09 EA EA200701159A patent/EA200701159A1/ru unknown
- 2005-12-09 JP JP2007545905A patent/JP2008524136A/ja active Pending
- 2005-12-09 CA CA002589493A patent/CA2589493A1/en not_active Abandoned
- 2005-12-09 KR KR1020077016354A patent/KR20070097511A/ko not_active Withdrawn
- 2005-12-09 BR BRPI0519656-6A patent/BRPI0519656A2/pt not_active Application Discontinuation
- 2005-12-09 AU AU2005315855A patent/AU2005315855A1/en not_active Abandoned
- 2005-12-09 CN CNA2005800434334A patent/CN101080225A/zh active Pending
- 2005-12-09 EP EP05814002A patent/EP1827424A1/en not_active Withdrawn
- 2005-12-09 WO PCT/EP2005/013224 patent/WO2006063737A1/en active Application Filing
- 2005-12-15 PE PE2005001465A patent/PE20060768A1/es not_active Application Discontinuation
- 2005-12-16 AR ARP050105303A patent/AR052052A1/es unknown
- 2005-12-16 TW TW094144909A patent/TW200637546A/zh unknown
- 2005-12-20 UY UY29274A patent/UY29274A1/es not_active Application Discontinuation
-
2007
- 2007-05-04 NO NO20072325A patent/NO20072325L/no not_active Application Discontinuation
- 2007-06-14 IL IL183944A patent/IL183944A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070097511A (ko) | 2007-10-04 |
| AU2005315855A1 (en) | 2006-06-22 |
| WO2006063737A1 (en) | 2006-06-22 |
| JP2008524136A (ja) | 2008-07-10 |
| EP1827424A1 (en) | 2007-09-05 |
| TW200637546A (en) | 2006-11-01 |
| EA200701159A1 (ru) | 2007-12-28 |
| IL183944A0 (en) | 2007-10-31 |
| UY29274A1 (es) | 2006-07-31 |
| CA2589493A1 (en) | 2006-06-22 |
| AR052052A1 (es) | 2007-02-28 |
| NO20072325L (no) | 2007-07-06 |
| BRPI0519656A2 (pt) | 2009-03-03 |
| CN101080225A (zh) | 2007-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060768A1 (es) | Composicion farmaceutica que comprende hidroclorotiazida y telmisartano | |
| PE20061449A1 (es) | Composiciones farmaceuticas comprendiendo imatinib y un retardador de liberacion | |
| BRPI0507887A (pt) | comprimido de múltiplas camadas | |
| PH12012501282A1 (en) | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof | |
| DOP2004000907A (es) | Procedimientos y composiciones farmaceuticas para tratar aterosclerosis dislipidemias y afecciones relacionadas | |
| BRPI0514474A (pt) | multiparticulados | |
| GT200800060A (es) | Derivados de espiro aza-sustituidos | |
| AR040014A1 (es) | Combinacion de compuestos organicos | |
| AR065096A1 (es) | Preparacion solida | |
| ATE380547T1 (de) | Zweischichtige pharmazeutische tablette enthaltend telmisartan und hydrochlorothiazid | |
| CY1109719T1 (el) | Σκευασμα 1-[(3-υδροξυ-αδαμαντ-1-υλαμινο)-ακετυλο]-πυρρολιδινο-2-(s)-καρβονιτριλιου τροποποιημενης απελευθερωσης | |
| PE20020082A1 (es) | Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1) | |
| CL2008001946A1 (es) | Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas. | |
| AR069031A1 (es) | Composicion | |
| WO2006102308A3 (en) | Beta-lactamyl vasopressin v1b antagonists | |
| AR061446A1 (es) | Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico | |
| ATE415947T1 (de) | Verwendung von stärke mit abgespaltenen seitenketten in der extrudierung / spheronisierung von pharmazeutischen pellets | |
| AR067077A1 (es) | Preparado solido farmaceutico y metodo de produccion del mismo | |
| ATE513830T1 (de) | Phenothiazin-derivate mit doppelbindung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| CO6361995A2 (es) | Derivados de isoquinolinona como antagonistas de nk3 | |
| CL2008001678A1 (es) | Forma de dosificación farmacéutica de liberacion prolongada en forma de comprimido, que consiste de nevirapina anhidra, hipromelosa, lactosa monohidrato y estearato de magnesio; y su procedimiento de preparación, util para el tratamiento de una infeccion por vih-1. | |
| AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
| PE20120421A1 (es) | Composicion farmaceutica que comprende aleglitazar | |
| CL2009000896A1 (es) | Compuestos derivados de 3-fenilpirazolo[5,1-b]tiazol sustituido; composicion farmaceutica; utiles en el tratamiento de la depresion, ansiedad, isquemia, apoplejia, hipertension, esquizofrenia, entre otras enfermedades. | |
| UA100883C2 (ru) | Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |